Multisystem Inflammatory Syndrome in an Adult Following COVID-19 mRNA Vaccination : Successful Treatment With Medium-Dose Steroids and Colchicine
© 2022 The Korean Academy of Medical Sciences..
Multisystem inflammatory syndrome in children and adults (MIS-C/A) was rarely reported as a complication of coronavirus disease 2019 (COVID-19) and potential adverse events following COVID-19 vaccination. Recently, the case definition of MIS-C/A was developed by the Brighton Collaboration Network. However, only a limited number of adult patients with MIS-A following immunization have been reported, and there is still little evidence for adequate treatment. A 57-year-old man presented with fever, headache, vomiting, and hypotension 24 days after receiving the second COVID-19 vaccination with the Pfizer-BioNTech vaccine. According to the Brighton Collaboration Case Definition, the patient met a definitive case of MIS-A after vaccination (level 1 of diagnostic certainty). After administration of medium-dose prednisolone (20 mg/d) with colchicine (1.2 mg/d), all symptoms and signs improved rapidly. The dose of prednisolone was gradually tapered from the third week, and the patient confirmed a full recovery without medication after 8 weeks. This is the first report showing that low-dose steroids in combination with colchicine may be an effective treatment option for MIS-A after vaccination.
| Errataetall: |
CommentIn: J Korean Med Sci. 2022 Dec 26;37(50):e357. - PMID 36573390 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of Korean medical science - 37(2022), 41 vom: 24. Okt., Seite e299 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Hyo-Jin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9PHQ9Y1OLM |
|---|
| Anmerkungen: |
Date Completed 27.10.2022 Date Revised 27.12.2022 published: Electronic CommentIn: J Korean Med Sci. 2022 Dec 26;37(50):e357. - PMID 36573390 Citation Status MEDLINE |
|---|
| doi: |
10.3346/jkms.2022.37.e299 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34796057X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34796057X | ||
| 003 | DE-627 | ||
| 005 | 20231226035052.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3346/jkms.2022.37.e299 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM34796057X | ||
| 035 | |a (NLM)36281487 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Hyo-Jin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multisystem Inflammatory Syndrome in an Adult Following COVID-19 mRNA Vaccination |b Successful Treatment With Medium-Dose Steroids and Colchicine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2022 | ||
| 500 | |a Date Revised 27.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: J Korean Med Sci. 2022 Dec 26;37(50):e357. - PMID 36573390 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Korean Academy of Medical Sciences. | ||
| 520 | |a Multisystem inflammatory syndrome in children and adults (MIS-C/A) was rarely reported as a complication of coronavirus disease 2019 (COVID-19) and potential adverse events following COVID-19 vaccination. Recently, the case definition of MIS-C/A was developed by the Brighton Collaboration Network. However, only a limited number of adult patients with MIS-A following immunization have been reported, and there is still little evidence for adequate treatment. A 57-year-old man presented with fever, headache, vomiting, and hypotension 24 days after receiving the second COVID-19 vaccination with the Pfizer-BioNTech vaccine. According to the Brighton Collaboration Case Definition, the patient met a definitive case of MIS-A after vaccination (level 1 of diagnostic certainty). After administration of medium-dose prednisolone (20 mg/d) with colchicine (1.2 mg/d), all symptoms and signs improved rapidly. The dose of prednisolone was gradually tapered from the third week, and the patient confirmed a full recovery without medication after 8 weeks. This is the first report showing that low-dose steroids in combination with colchicine may be an effective treatment option for MIS-A after vaccination | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Adult Multisystem Inflammatory Syndrome | |
| 650 | 4 | |a COVID-19 Vaccine | |
| 650 | 4 | |a Colchicine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Steroids | |
| 650 | 7 | |a Colchicine |2 NLM | |
| 650 | 7 | |a SML2Y3J35T |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Prednisolone |2 NLM | |
| 650 | 7 | |a 9PHQ9Y1OLM |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Steroids |2 NLM | |
| 700 | 1 | |a Jeong, Yeon Jeong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Youn Jeong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Si-Hyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Korean medical science |d 1995 |g 37(2022), 41 vom: 24. Okt., Seite e299 |w (DE-627)NLM012649317 |x 1598-6357 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2022 |g number:41 |g day:24 |g month:10 |g pages:e299 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3346/jkms.2022.37.e299 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2022 |e 41 |b 24 |c 10 |h e299 | ||